Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson’s disease

Han Soo Yoo, Jun Sung Lee, Seok Jong Chung, Byoung Seok Ye, Young H. Sohn, Seung Jae Lee, Phil Hyu Lee

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Lysosomal dysfunction has been associated with Parkinson’s disease (PD). However, the activity of lysosomal enzymes is heterogeneously observed in PD. We investigated whether arylsulfatase A (ARSA) level can be used as a fluid biomarker of PD and can reflect disease progression. Plasma ARSA level was measured in 55 patients with early and drug-naïve PD, 13 patients with late PD, and 14 healthy controls. We compared the plasma ARSA level among the groups and assessed its correlation to clinical parameters and striatal dopamine transporter (DAT) activity. Plasma ARSA level was not correlated with age. The early PD group had higher plasma ARSA level than the control and late PD groups. In a generalized additive model including all patients with PD, the plasma ARSA level showed an inverted U-shape according to disease duration, peaking at 2.19 years. In patients with early PD, plasma ARSA level was positively correlated to parkinsonian motor score and negatively to striatal DAT activity. In summary, plasma ARSA level was elevated in early stage of PD, and elevated plasma ARSA level was correlated to the clinical and imaging markers of nigrostriatal degeneration. These results suggest that ARSA level is a potential biomarker of compensation in early PD.

Original languageEnglish
Article number5567
JournalScientific reports
Issue number1
Publication statusPublished - 2020 Dec 1

Bibliographical note

Publisher Copyright:
© 2020, The Author(s).

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson’s disease'. Together they form a unique fingerprint.

Cite this